Detailed imaging and genetic analysis reveal a secondary BRAFL505H resistance mutation and extensive intrapatient heterogeneity in metastatic BRAF mutant melanoma patients treated with vemurafenib
暂无分享,去创建一个
E. Cuppen | O. Krijgsman | D. Peeper | E. Voest | M. Hoogstraat | W. Veldhuis | C. G. Gadellaa-van Hooijdonk | M. Koudijs | S. Willems | N. Besselink | M. Lolkema | Mark Pieterse | T. Kuilman | M. Hadders | M. Stralen | I. Ubink | E. Meijer | Nicolle J. M. Besselink